Understanding sex differences in the regulation of cancer-induced muscle wasting

Purpose of review We highlight evidence for sexual dimorphism in preclinical and clinical studies investigating the cause and treatment of cancer cachexia. Recent findings Cancer cachexia is unintended bodyweight loss occurring with cancer, and skeletal muscle wasting is a critical predictor of negative outcomes in the cancer patient. Skeletal muscle exhibits sexual dimorphism in fiber type, function, and regeneration capacity. Sex differences have been implicated in skeletal muscle metabolism, mitochondrial function, immune response to injury, and myogenic stem cell regulation. All of these processes have the potential to be involved in cancer-induced muscle wasting. Unfortunately, the vast majority of published studies examining cancer cachexia in preclinical models or cancer patients either have not accounted for sex in their design or have exclusively studied males. Preclinical studies have established that ovarian function and estradiol can affect skeletal muscle function, metabolism and mass; ovarian function has also been implicated in the sensitivity of circulating inflammatory cytokines and the progression of cachexia. Summary Females and males have unique characteristics that effect skeletal muscle's microenvironment and intrinsic signaling. These differences provide a strong rationale for distinct causes for cancer cachexia development and treatment in males and females.
Source: Current Opinion in Supportive and Palliative Care - Category: Palliative Care Tags: CACHEXIA, NUTRITION AND HYDRATION: Edited by Aminah Jatoi and Barry J.A. Laird Source Type: research

Related Links:

Authors: Daly MB Abstract The National Comprehensive Cancer Network (NCCN) clinical practice guidelines have become the most recognized standard for clinical policy in cancer care. The Genetic Breast and Ovarian Guideline was introduced in 1999 with an emphasis on BRCA1/2. Based on evidence linking prostate cancer to the BRCA genes, prostate cancer was added to the guideline as a criterion for risk assessment in 2013. The current criteria include aggressive/metastatic disease and family history of BRCA-related cancers. PMID: 31629424 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Conclusions Discontinuous dosing of olaparib resulted in significant myelosuppression leading to dose interruptions and/or delays. Anti-tumor activity was encouraging in patients enriched with BRCA-mutated breast and ovarian cancer. The most appropriate olaparib tablet dose for use in further studies evaluating olaparib in combination with carboplatin and paclitaxel is 50 mg bid (days 1 –5).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
AbstractOvarian cancer is one of the most lethal gynecological cancers; owning to its late detection and chemoresistance, understanding the pathogenesis of this malignant tumor is much critical. Previous studies have reported that ubiquitin-specific peptidase 39 (USP39) is generally overexpressed in a variety of cancers, including hepatocellular carcinoma, gastric cancer and so forth. Furthermore, USP39 is proved to be associated with the proliferation of malignant tumors. However, the function and mechanism of USP39 in ovarian cancer have not been elucidated. In the present study, we observed that USP39 was frequently ove...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Mitra Most ovarian cancer patients present with disseminated disease at the time of their diagnosis, which is one of the main reasons for their poor prognosis. Metastasis is a multi-step process and a clear understanding of the mechanism of regulation of these steps remains elusive. Productive reciprocal interactions between the metastasizing ovarian cancer cells and the microenvironment of the metastatic site or the tumor microenvironment play an important role in the successful establishment of metastasis. Much progress has been made in the recent past in our understanding of such interactions and the role of the ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study aimed to clarify the molecular mechanism of LINC01133 in the progression of ovarian cancer. Initially, microarray-based analysis was used to screen differentially expressed long noncoding RNAs and miRNAs, with LINC01133 and miR-205 obtained for this study. The biological functions of LINC01133, miR-205, and leucine-rich repeat kinase 2 (LRRK2) were validated on cell proliferation, migration, and invasion of ovarian cancer through gain-of-function and loss-of-function experiments.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Regular article Source Type: research
In conclusion, pinocembrin inhibited the proliferation and migration and promoted the apoptosis of ovarian cancer cells through down-regulating the mRNA levels of N-cadherin and GABAB receptor.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Authors: Gupta S, Pathak Y, Gupta MK, Vyas SP Abstract Ovarian cancer is the second most common gynaecological malignancy. It usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with poor diagnosis. Despite the chemosensitivity of intraperitoneal chemotherapy, the majority of patients is relapsed and eventually dies. In addition to the challenge of early detection, its treatment presents several challenges like the route of administration, resistance to therapy with recurrence and specific targeting of cancer to reduce cytotoxicity and side ...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Conclusion: Pelvic exenteration remains an important treatment in selected patients with advanced or recurrent nonrectal pelvic malignancy. The range in 3-year overall survival following R0 resection (40%–59%) reflects the diversity of tumor types.
Source: Annals of Surgery - Category: Surgery Tags: ESA PAPERS Source Type: research
Publication date: Available online 19 October 2019Source: Respiratory Medicine Case ReportsAuthor(s): V.R. Anjali, Rambha Pandey, Astha Srivastava, Madhu Rajeshwari, Durgatosh Pandey, M.C. SharmaAbstractWith the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell lung cancer are commonly EGFR (Epidermal Growth Factor Receptor) gene mutation and ALK (Anaplastic Lymphoma Kinase) gene rearran...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Estradiol | Nutrition | Ovarian Cancer | Ovaries | Palliative | Palliative Care | Stem Cell Therapy | Stem Cells | Study